Departmento de Medicina Intensiva, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago.
Fundación Valle del Lili, Universidad ICESI, Department of Intensive Care Medicine, Cali, Colombia.
JAMA. 2019 Feb 19;321(7):654-664. doi: 10.1001/jama.2019.0071.
Abnormal peripheral perfusion after septic shock resuscitation has been associated with organ dysfunction and mortality. The potential role of the clinical assessment of peripheral perfusion as a target during resuscitation in early septic shock has not been established.
To determine if a peripheral perfusion-targeted resuscitation during early septic shock in adults is more effective than a lactate level-targeted resuscitation for reducing mortality.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized trial conducted at 28 intensive care units in 5 countries. Four-hundred twenty-four patients with septic shock were included between March 2017 and March 2018. The last date of follow-up was June 12, 2018.
Patients were randomized to a step-by-step resuscitation protocol aimed at either normalizing capillary refill time (n = 212) or normalizing or decreasing lactate levels at rates greater than 20% per 2 hours (n = 212), during an 8-hour intervention period.
The primary outcome was all-cause mortality at 28 days. Secondary outcomes were organ dysfunction at 72 hours after randomization, as assessed by Sequential Organ Failure Assessment (SOFA) score (range, 0 [best] to 24 [worst]); death within 90 days; mechanical ventilation-, renal replacement therapy-, and vasopressor-free days within 28 days; intensive care unit and hospital length of stay.
Among 424 patients randomized (mean age, 63 years; 226 [53%] women), 416 (98%) completed the trial. By day 28, 74 patients (34.9%) in the peripheral perfusion group and 92 patients (43.4%) in the lactate group had died (hazard ratio, 0.75 [95% CI, 0.55 to 1.02]; P = .06; risk difference, -8.5% [95% CI, -18.2% to 1.2%]). Peripheral perfusion-targeted resuscitation was associated with less organ dysfunction at 72 hours (mean SOFA score, 5.6 [SD, 4.3] vs 6.6 [SD, 4.7]; mean difference, -1.00 [95% CI, -1.97 to -0.02]; P = .045). There were no significant differences in the other 6 secondary outcomes. No protocol-related serious adverse reactions were confirmed.
Among patients with septic shock, a resuscitation strategy targeting normalization of capillary refill time, compared with a strategy targeting serum lactate levels, did not reduce all-cause 28-day mortality.
ClinicalTrials.gov Identifier: NCT03078712.
脓毒性休克复苏后外周灌注异常与器官功能障碍和死亡率有关。外周灌注评估作为早期脓毒性休克复苏过程中的目标的潜在作用尚未确定。
确定在成人早期脓毒性休克中,以外周灌注为目标的复苏是否比以乳酸水平为目标的复苏更能降低死亡率。
设计、地点和参与者:这是一项在 5 个国家的 28 个重症监护病房进行的多中心随机试验。纳入了 2017 年 3 月至 2018 年 3 月期间的 424 名脓毒性休克患者。最后随访日期为 2018 年 6 月 12 日。
患者被随机分配到一个逐步复苏方案,该方案旨在使毛细血管再充盈时间正常化(n=212),或使乳酸水平正常化或在 2 小时内降低超过 20%(n=212),在 8 小时的干预期间。
主要结局为 28 天的全因死亡率。次要结局为随机分组后 72 小时的器官功能障碍,采用序贯器官衰竭评估(SOFA)评分(范围,0 [最佳]至 24 [最差])评估;90 天内死亡;28 天内机械通气、肾脏替代治疗和无血管加压素天数;重症监护病房和医院的住院时间。
在 424 名随机分组的患者(平均年龄 63 岁;226 [53%] 为女性)中,有 416 名(98%)完成了试验。在第 28 天,外周灌注组有 74 名患者(34.9%)和乳酸组有 92 名患者(43.4%)死亡(风险比,0.75 [95% CI,0.55 至 1.02];P=0.06;风险差异,-8.5% [95% CI,-18.2% 至 1.2%])。外周灌注靶向复苏与 72 小时时较少的器官功能障碍相关(平均 SOFA 评分,5.6 [SD,4.3] vs 6.6 [SD,4.7];平均差异,-1.00 [95% CI,-1.97 至 -0.02];P=0.045)。其他 6 项次要结局无显著差异。未确认与方案相关的严重不良事件。
在脓毒性休克患者中,与以血清乳酸水平为目标的复苏策略相比,以毛细血管再充盈时间正常化为目标的复苏策略并未降低 28 天的全因死亡率。
ClinicalTrials.gov 标识符:NCT03078712。